Stephanie M. Lawley

Overview

Ms. Lawley has extensive experience drafting and prosecuting patent applications in the U.S. and many foreign countries.  Her practice focuses on biological and chemical technologies.  She has experience counseling clients regarding portfolio management and rendering opinions regarding patent validity, infringement, patentability, freedom-to-operate, and inventorship.

Experience

Technologies with which Ms. Lawley has been involved include vaccines, microarray technologies, expression vectors, proteins, chemical and biological assays, antibodies, stem cells, immunotherapies, pharmaceutical compositions and formulations, antisense therapy, chimeric antigen receptors, engineered cells, gene therapies, molecular biology techniques, medical diagnostics, personalized medicine, nucleic acid sequences, blood filters, fire retardants, fluid separation technologies, and nutritional supplements.  Ms. Lawley also has experience handling appeals to The Patent Trial and Appeal Board (PTAB) and an inter partes reexamination proceeding.

Education

• George Mason University, J.D., 2004
• College of William and Mary, M.A. in Biology, 2001
• Mary Baldwin College, B.S. in Biochemistry, magna cum laude, 1999
  • Phi Beta Kappa

Admissions

• District of Columbia, 2005
• Virginia, 2004
• Registered to practice before the U.S. Patent and Trademark Office

Courts

• U.S. Court of Appeals for the District of Columbia
• U.S. District Court for the Eastern District of Virginia

Professional Affiliations

• Intellectual Property Owners Association (IPO)

Languages

• German

Practices

• Patent Preparation and Prosecution

Technologies

• Biotechnology
• Chemical Technologies
• Mechanical, Electromechanical, and Optical Technologies
• Pharmaceuticals and Biosimilars

Insights

• Leydig Announces 2024 Board of Directors and Officers
  March 14, 2024
• Stephanie Lawley Discusses New USPTO Examination Guidelines for Evaluating Patent Enablement in view of Amgen Decision
  January 24, 2024
• Stephanie Lawley Presents “Amgen v. Sanofi and Enablement Requirements” at Biopatent Forum in Frankfurt, Germany
  June 21, 2023
• US Supreme Court Rules that USPTO Director May Review Decisions by the PTAB.
  June 21, 2021